Inhibrx Biosciences, Inc.
INBX
$14.93
-$0.28-1.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 9.51% | -9.12% | -102.40% | 2,423.18% | 15.91% |
| Total Depreciation and Amortization | -2.03% | -9.34% | 59.66% | 32.22% | 20.81% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | 66.26% | -0.40% |
| Total Other Non-Cash Items | -16.45% | -0.32% | 100.18% | -28,529.10% | -0.31% |
| Change in Net Operating Assets | 83,000.00% | -99.96% | -76.36% | 450.25% | -74.62% |
| Cash from Operations | 17.90% | -44.38% | 62.19% | -27.03% | -10.96% |
| Capital Expenditure | -31.25% | 93.52% | 79.67% | -8.58% | 67.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -31.25% | 93.52% | 79.67% | -8.58% | 67.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | 85.08% | 3,469.40% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -100.00% | -21.90% | 4,403.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 246.16% | -43.27% | 40.22% | -100.72% | 57.17% |